A study of changes in SGPT and SGOT over time the patients of drug induced hepatitis taking antitubercular drugs

 

Abhijit Sayamber

 

Assistant Professor, Department of Pulmonary Medicine, P. D. V. V. P. F. S. Medical College, Ahmednagar, Maharashtra, INDIA.

Email: abhijit.sayamber@gmail.com

REFERENCES

 

1. Gronhagen-riska, C.,P.E.Hellstrom, and B. Froseth. 1978. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am. Rev. Respir. Dis. 118: 461-466
2. Steele MA, Burk RF, Desprez RM. Hepatitis with insoniazid and rifampicin; a meta-analysis. Chest 1991; 99:465-71.
3. Singh J, Garg PK, Tandon RK, Hepatotxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J ClinGastroneterol 1996; 22(3): 211-4.
4. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. evaluation of clinical and immuunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J RespirCrit Care Med 2002; 166-119.
5. Pande J N, singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
6. Huang Y S, Chern H D, Su W J, et al. polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug induced hepatitis. Hepatology 2002; 35:885-889.
7. Singh J, Garg PK, Tandon RK, Hepatotxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J ClinGastroneterol 1996; 22(3): 211-4.
8. Dull AK, moers. D. Slead WW. Short course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampicin: community physicians’ seven year experience with mainly outpatients. Am J med 1984: 77: 233-42.
9. Steele MA, Burk RF, Desprez RM. Hepatitis with insoniazid and rifampicin; a meta-analysis. Chest 1991; 99:465-71.
10. Singh J, Arora A, Garg P K, Thakur V S, Pande J N, Tandon R K. antituberculosis treatment – induced hepatotxicity: role of predictive factors. Postgrad med J 1995; 71: 359-362.
11. Mahashur AA, Prabhudesai PP. Hepatitis and antitubercular therapy. J Assochysicians India 1991; 39: 595-6.
12. Rajani Shakya Rao B.S., BhawanaShriestha; Evaluation of risk factors for anti tuberculous drug induced hepatoloxicity in Nepalese population; Kathamandu university Journal of sciences, Engeenering and technology VOL. II, No. 1 Feb., 2006.
13. Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment; Col. A.C. Anand V.SM., Lt. Col. AK. Seth, Lt. Col. M. Paul, Lt. Col. P. Puri; MJAFI, Vol. 62, No. 1. 2006.
14. Huang Y S, Chern H D, Su W J, et al. polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug induced hepatitis. Hepatology 2002; 35:885-889.
15. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997; 34: 758-760.
16. Drug induced liver disease; mechanism of anti tuberculous drug induced liver damage; Neil Kaplowitz, Laurie D. Deleve, 505-519; 2nd Edi.; 2007.
17. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. antimicrob. Agents. Chemother. 2001; 45: 382-392.
18. Drug induced liver disease; mechanism of anti tuberculous drug induced liver damage; Neil Kaplowitz, Laurie D. Deleve, 505-519; 2nd Edi.; 2007.
19. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydralazine. Metabolites. Clin. Pharmacol. Ther. 1975; 18: 70-79
20. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997; 34: 758-760.